Proteostasis Therapeutics, Inc. (PTI) Analysts See $-0.65 EPS

March 15, 2018 - By Adrian Mccoy

 Proteostasis Therapeutics, Inc. (PTI) Analysts See $ 0.65 EPS

Analysts expect Proteostasis Therapeutics, Inc. (NASDAQ:PTI) to report $-0.65 EPS on March, 29.They anticipate $0.27 EPS change or 71.05 % from last quarter’s $-0.38 EPS. After having $-0.56 EPS previously, Proteostasis Therapeutics, Inc.’s analysts see 16.07 % EPS growth. The stock increased 2.74% or $0.175 during the last trading session, reaching $6.555. About 13.48 million shares traded or 778.75% up from the average. Proteostasis Therapeutics, Inc. (NASDAQ:PTI) has declined 66.87% since March 15, 2017 and is downtrending. It has underperformed by 83.57% the S&P500.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. The company has market cap of $217.05 million. The Company’s lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. It currently has negative earnings. The firm is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response modulators that are in preclinical development.

More important recent Proteostasis Therapeutics, Inc. (NASDAQ:PTI) news were published by: which released: “Mid-Day Market Update: Crude Oil Down 1.5%; Proteostasis Therapeutics Shares …” on March 13, 2018, also published article titled: “Proteostasis Therapeutics Inc (PTI) Soars on Cystic Fibrosis Approval”, published: “Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy …” on March 12, 2018. More interesting news about Proteostasis Therapeutics, Inc. (NASDAQ:PTI) was released by: and their article: “Proteostasis Therapeutics to Present at the Cowen and Company 38th Annual …” with publication date: March 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.